Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
- 4 October 2025
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (12) , 2286-2292
Abstract
Light chain multiple myeloma (LCMM) is a subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains and accounts for 15%–20% of newly diagnosed MM. A comprehensive comparison of LCMM with MM producing intact immunoglobulin (non‐LCMM) remains limited. In this retrospective study, we described distinct clinical and cytogenetic features and assessed long‐term outcomes in 852 LCMM patients diagnosed between 01/01/2004 and 12/31/2022, compared with non‐LCMM controls matched for age, sex, and year of diagnosis. On univariable analysis, LCMM patients were more likely to present with elevated creatinine (> 2 mg/dL), beta‐2‐microglobulin ≥ 5.5 mg/L, elevated LDH, hypercalcemia, t(11;14), del(13q), and t(6;14). Conversely, IMS‐IMWG high‐risk disease, hyperdiploidy, t(4;14), and serum albumin < 3.5 g/dL were less common. On multivariable analysis, elevated creatinine (OR: 5.1, 95% CI: 1.2–27, p = 0.04), t(11;14) (OR: 2.6, 95% CI: 1.3–5.2, p = 0.006), and del(13q) (OR: 4.1, 95% CI: 2.1–8.2, p < 0.001) were independently associated with LCMM, while IMS‐IMWG high‐risk disease (OR: 0.3, 95% CI: 0.1–0.8, p = 0.02) and hyperdiploidy (OR: 0.3, 95% CI: 0.1–0.7, p = 0.002) were less frequent. Despite these differences, progression‐free survival with frontline treatment (HR: 0.97, 95% CI: 0.84–1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87–1.13, p = 0.94) were similar between LCMM and non‐LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS‐IMWG high‐risk disease, and comparable survival outcomes.Keywords
This publication has 24 references indexed in Scilit:
- Multiple myeloma with acute light chain cast nephropathyBlood Cancer Journal, 2023
- Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myelomaBlood Cancer Journal, 2022
- Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)Journal of Cancer Research and Clinical Oncology, 2021
- Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseBlood Cancer Journal, 2020
- Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)Journal of Cancer Research and Clinical Oncology, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myelomaBlood Cancer Journal, 2015
- Relationship between initial clinical presentation and the molecular cytogenetic classification of myelomaLeukemia, 2013
- Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney BiopsiesAmerican Journal of Kidney Diseases, 2012
- Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variantsBlood, 2003